Centessa appoints Raphael Deferiere as Chief Accounting Officer

Centessa Pharmaceuticals plc

Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.
Base salary of $400,000; annual bonus target 35% of base; option for 165,000 ADSs.
Option vests 25% at one year, then 36 equal monthly installments.
Mr. Deferiere was an Assurance Partner at Ernst & Young LLP (July 2017 – May 2025).

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

John Crowley

Chief Financial Officer

CNTA · Centessa Pharmaceuticals plc

Effective: 2025-05-27
Filed: May 29, 2025 23:59 UTC

Mr. Deferiere assumes the designation of principal accounting officer from John Crowley, who continues in his capacity as Chief Financial Officer and the Company’s principal financial officer.

Appointed

Raphael Deferiere

Chief Accounting Officer

CNTA · Centessa Pharmaceuticals plc

Effective: 2025-05-27
Filed: May 29, 2025 23:59 UTC

On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025.

Source: SEC EDGAR

accession 0001847903-25-000081

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.